Evox Therapeutics
Jun 11, 2020
AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;
AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
